Product Description
Ertugliflozin is used along with diet and exercise, and sometimes with other medications, to lower blood sugar levels in people with type 2 diabetes (condition in which blood sugar is too high because the body does not produce or use insulin normally). Ertugliflozin is in a class of medications called sodium-glucose co-transporter 2 (SGLT2) inhibitors. It lowers blood sugar by causing the kidneys to get rid of more glucose in the urine. Ertugliflozin is not used to treat type 1 diabetes (condition in which the body does not produce insulin and, therefore, cannot control the amount of sugar in the blood) or diabetic ketoacidosis (a serious condition that may develop if high blood sugar is not treated). (Sourced from: https://medlineplus.gov/druginfo/meds/a618011.html)
Mechanisms of Action: SGLT2 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Canada | Chile | Croatia | Cyprus | Czech | Denmark | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Netherlands | Norway | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | Spain | Sweden | Switzerland | Taiwan | United Arab Emirates | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Canada, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Israel, Italy, Korea, Malaysia, Mauritius, Mexico, Philippines, Poland, Russia, Saudi Arabia, Ukraine, United Arab Emirates, United Kingdom, United States, Unknown Location
Active Clinical Trial Count: 5
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Mitral Valve Insufficiency|Type 2 Diabetes|Ventricular Dysfunction, Left
Phase 2: Heart Failure
Phase 1: Atherosclerosis|Insulin Resistance
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| Ertugliflozin | P1 |
Completed |
Atherosclerosis|Insulin Resistance|Type 2 Diabetes |
2023-12-31 |
23% |
2024-12-21 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
| MISP59625 | P2 |
Recruiting |
Heart Failure |
2025-12-30 |
12% |
2025-08-27 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
| MK-8835-059 | P3 |
Completed |
Type 2 Diabetes |
2025-04-11 |
64% |
2025-11-01 |
Patient Enrollment|Primary Endpoints |
| EFFORT | P3 |
Completed |
Mitral Valve Insufficiency|Ventricular Dysfunction, Left |
2023-11-15 |
13% |
2023-11-22 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
| MK-8835-059 | P3 |
Completed |
Type 2 Diabetes |
2024-11-19 |
64% |
2025-05-02 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
12/05/2024 |
News Article |
Wedgewood Launches Blue Rabbit for Equine Veterinarians at AAEP |
|
05/15/2024 |
News Article |
BioAge Labs Announces Inaugural Scientific Advisory Board to Support Advancement of Novel Therapeutics Targeting Metabolic Aging |
|
01/10/2024 |
News Article |
A New Study Shows GlycoMark is a Novel Biomarker of SGLT-2i Adherence |
|
01/10/2024 |
News Article |
A New Study Shows GlycoMark is a Novel Biomarker of SGLT-2i Adherence |